603 related articles for article (PubMed ID: 28142287)
1. Overview and recent advances in the treatment of neuroblastoma.
Whittle SB; Smith V; Doherty E; Zhao S; McCarty S; Zage PE
Expert Rev Anticancer Ther; 2017 Apr; 17(4):369-386. PubMed ID: 28142287
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma: Therapeutic strategies for a clinical enigma.
Modak S; Cheung NK
Cancer Treat Rev; 2010 Jun; 36(4):307-17. PubMed ID: 20227189
[TBL] [Abstract][Full Text] [Related]
3. Anti-GD2 immunotherapy for neuroblastoma.
Sait S; Modak S
Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
[TBL] [Abstract][Full Text] [Related]
4. Novel Therapies for Relapsed and Refractory Neuroblastoma.
Zage PE
Children (Basel); 2018 Oct; 5(11):. PubMed ID: 30384486
[TBL] [Abstract][Full Text] [Related]
5. Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.
Newman EA; Nuchtern JG
Semin Pediatr Surg; 2016 Oct; 25(5):257-264. PubMed ID: 27955728
[TBL] [Abstract][Full Text] [Related]
6. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
[TBL] [Abstract][Full Text] [Related]
7. Current management of neuroblastoma and future direction.
Pastor ER; Mousa SA
Crit Rev Oncol Hematol; 2019 Jun; 138():38-43. PubMed ID: 31092383
[TBL] [Abstract][Full Text] [Related]
8. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.
Zage PE; Louis CU; Cohn SL
Pediatr Blood Cancer; 2012 Jul; 58(7):1099-105. PubMed ID: 22378620
[TBL] [Abstract][Full Text] [Related]
9. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
Owens C; Irwin M
Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
[TBL] [Abstract][Full Text] [Related]
10. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
11. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.
Liang WH; Federico SM; London WB; Naranjo A; Irwin MS; Volchenboum SL; Cohn SL
JCO Clin Cancer Inform; 2020 Oct; 4():895-905. PubMed ID: 33058692
[TBL] [Abstract][Full Text] [Related]
12. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
Défachelles AS; Cougnenc O; Carpentier P
Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
[TBL] [Abstract][Full Text] [Related]
13. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
14. State of the art in immunotherapy of neuroblastoma.
Jabbari P; Hanaei S; Rezaei N
Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
[TBL] [Abstract][Full Text] [Related]
15. Methodological advances in the discovery of novel neuroblastoma therapeutics.
Segura MF; Soriano A; Roma J; Piskareva O; Jiménez C; Boloix A; Fletcher JI; Haber M; Gray JC; Cerdá-Alberich L; Martínez de Las Heras B; Cañete A; Gallego S; Moreno L
Expert Opin Drug Discov; 2022 Feb; 17(2):167-179. PubMed ID: 34807782
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapeutic targets for neuroblastoma.
Aravindan N; Herman T; Aravindan S
Expert Opin Ther Targets; 2020 Sep; 24(9):899-914. PubMed ID: 33021426
[TBL] [Abstract][Full Text] [Related]
17. The quest to develop an effective therapy for neuroblastoma.
Bhoopathi P; Mannangatti P; Emdad L; Das SK; Fisher PB
J Cell Physiol; 2021 Nov; 236(11):7775-7791. PubMed ID: 33834508
[TBL] [Abstract][Full Text] [Related]
18. Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P; Cañete A; Castel V
Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
20. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.
Cole KA; Maris JM
Clin Cancer Res; 2012 May; 18(9):2423-8. PubMed ID: 22427348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]